Pharmacovigilance – News and Features

UCSF researchers have engineered T cells to temper overactive immune responses by targeting inflammation and soothing immune activity. The technology successfully protected transplanted pancreatic islet cells in a type 1 diabetes model.

Discover how regulators are utilizing non-target and suspect screening to detect and prioritize emerging contaminants, shaping environmental monitoring strategies.

The therapy molecule AZD7648 can promote precise DNA repair during CRISPR gene editing, but creates massive genetic changes elsewhere.

Researchers have developed a revolutionary bone graft substitute inspired by coral which not only promotes faster healing but dissolves naturally in the body after the repair is complete.

Beta-blocker drugs commonly used to treat heart conditions may also slow the progression of Huntington's disease, a new study has found.

New research has identified a potential mechanism for cancer drug side effects that boost heart disease risk.

Synthetic biology techniques have emerged as transformative tools in the tug-of-war between humans and drug-resistant bacteria. Discover how researchers are utilizing synthetic biology techniques to engineer new antimicrobials.

A novel CAR T-cell therapy has benefitted patients with relapsed acute lymphoblastic leukemia, showing high response rates in a Phase Ib/II trial.

Researchers have developed programmable DNA nanostructures using DNA origami. These customizable nanobots have vast applications, from targeted drug delivery and adaptive materials to energy-efficient optical systems.

Benralizumab, a monoclonal antibody, is the first breakthrough in asthma and COPD flare-up treatment in 50 years. Targeting eosinophilic inflammation, it reduces steroid use by 30% and lowers treatment failure rates.